Lock Stock/Getty Images (NEW YORK) -- Regulators in Europe have launched a review after three people in Iceland experienced thoughts of suicide or self-harm after taking popular diabetes and weight loss drugs Ozempic and Saxenda. The review is being led by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee out of an abundance of caution. At this point, it's not clear if the three people in Iceland experienced thoughts of suicide or self-harm due to an underlying mental health condition, or whether these thoughts were related to starting drugs like Ozempic and Saxenda, which are called GLP-1 receptor agonists.

https://wadk.com/health-news/1aaaf532eba6c109583f56b2e7f5f1ee

#wadk